POLYPHARMACY: THE CLINICAL, PSYCHOLOGICAL, AND SYSTEMIC RISKS OF MULTIPLE MEDICATION USE

Dushayeva Nilufar Maxsudovna
Namangan davlat universiteti
Umumtibiy fanlar kafedrasi o'qituvchisi
nilufardusajeva@gmail.com
Ahmadjonova Tursunoy Anvarjon qizi
Namdu Pediatriya yo'nalishi talabasi

INTRODUCTION: THE SILENT EPIDEMIC OF MODERN MEDICINE

1. Definition and Taxonomic Evolution. Polypharmacy is no longer just a term for "many pills." In modern clinical practice, it is defined by the concurrent use of five or more medications. However, researchers now distinguish between Appropriate Polypharmacy (where multiple drugs are evidence-based and clinically necessary) and Inappropriate Polypharmacy (where medicines are prescribed without a clear indication, or the risk of harm outweighs the benefit).

2. Epidemiological Trends. As global healthcare systems shift toward managing chronic diseases, polypharmacy has reached epidemic proportions. In developed nations, approximately 50% of elderly patients are on five or more medications, and nearly 20% are on ten or more (hyper-polypharmacy). This is not merely a medical issue but a socioeconomic one, costing billions in avoidable hospital admissions annually.

SYSTEMIC DRIVERS AND THE "PRESCRIBING CASCADE"

1. The Pathophysiology of the Prescribing Cascade. The most insidious driver of polypharmacy is the prescribing cascade. This occurs when an adverse drug reaction (ADR) is misinterpreted as a new medical condition. For example:

- A patient is prescribed a **Calcium Channel Blocker** for hypertension.
- The drug causes peripheral edema (swelling).
- Instead of recognizing this as a side effect, the physician prescribes a **Diuretic** (water pill).
- The diuretic causes hypokalemia (low potassium) and gout.
- A third drug**, Allopurinol**, is then added.

Within months, a single-drug therapy evolves into a three-drug regimen, significantly increasing the chemical load on the patient's liver and kidneys.

2. Fragmentation of Care. In a specialized medical world, a patient with diabetes, heart disease, and arthritis may see three different specialists. Each specialist follows "Single-Disease Guidelines," often ignoring the medications prescribed by others. This lack of a "gatekeeper" (General Practitioner) leads to **Therapeutic Duplication**, where a patient might unknowingly take two different brands of the same drug class.

CLINICAL CONSEQUENCES AND PATHOPHYSIOLOGICAL RISKS

1. Pharmacokinetics and Pharmacodynamics in Aging. As the body ages, its ability to process chemicals changes significantly.

- **Renal Clearance:** Kidney function naturally declines, leading to higher concentrations of drugs in the blood.
- **Hepatic Metabolism:** The liver's cytochrome P450 enzyme system becomes saturated when processing multiple drugs, leading to dangerous Drug-Drug Interactions (DDIs).
- **Blood-Brain Barrier:** Becomes more permeable, making the elderly more susceptible to the central nervous system side effects of common medications (e.g., antihistamines causing profound confusion).

2. The Anticholinergic and Sedative Burden. Many drugs across different classes (antidepressants, bladder control, allergies) have "anticholinergic" properties. When combined, they create an **Anticholinergic Burden**, leading to:

- Acute delirium and cognitive decline.
- Dry mouth, blurred vision, and urinary retention.
- Increased risk of falls due to orthostatic hypotension (a sudden drop in blood pressure when standing).

3. Competitive Inhibition and Synergy. When five or more drugs are present, the risk of a "Major Interaction" increases to nearly **100%**. Competitive inhibition occurs when two drugs fight for the same receptor, rendering one useless. Conversely, synergy can be fatal—for example, the combination of blood thinners (Warfarin) and common NSAIDs (Ibuprofen) can lead to catastrophic internal bleeding.

PSYCHOSOCIAL IMPACT AND "PILL FATIGUE"

1. The Psychological Burden of Treatment. Polypharmacy creates a phenomenon known as **Treatment Burden**. Patients may spend hours a day organizing pills, checking schedules, and managing side effects. This often leads to **Pill Fatigue**, where the patient feels "over-medicalized," losing their sense of identity to their illness.

2. Medication Non-Adherence. Paradoxically, the more drugs a patient is prescribed, the less likely they are to take the ones they actually need. Complexity is the enemy of adherence. When a regimen exceeds 3 doses a day, adherence rates typically drop below 50%, leading to "rebound" effects and worsening of the underlying conditions.

THE SCIENCE OF DEPRESCRIBING: A NEW CLINICAL FRONTIER

1. Redefining Success in Medicine. Deprescribing is not about "giving up" on a patient; it is an active clinical process of tapering or stopping medications that are no longer beneficial. The goal is to improve Quality of Life (QoL) over simply "hitting numbers" (e.g., blood pressure targets).

2. Evidence-Based Tools (STOPP/START). Medical professionals utilize specialized criteria to identify dangerous prescriptions:

- **Beers Criteria:** Specifically lists drugs that increase the risk of falls and delirium in the elderly.

- **STOPP (Screening Tool of Older Persons' Prescriptions):** Helps identify drugs with no clinical indication.
- **START (Screening Tool to Alert to Right Treatment):** Ensures that while we cut bad drugs, we don't miss essential ones.

CONCLUSION: TOWARD A HOLISTIC PHARMACOLOGY

The dangers of polypharmacy represent a failure of the "more is better" philosophy in medicine. To combat this silent epidemic, a paradigm shift is required:

- **Medication Reconciliation:** At every hospital visit, every pill (including herbals) must be physically reviewed.
- **Shared Decision Making:** Patients must be involved in deciding which symptoms they want to prioritize.
- **Deprescribing Culture:** Shifting the medical mindset so that stopping a drug is viewed as just as much of a "cure" as starting one.

REFERENCES

1. Gnjidic, D., et al. (2012). "Polypharmacy and adverse drug reactions in older adults." Expert Opinion on Drug Safety.
2. Maher, R. L., et al. (2014). "Clinical consequences of polypharmacy in elderly." Expert Opinion on Drug Safety.
3. Reeve, E., et al. (2015). "Review of Deprescribing Processes and Predictors of Success." Drugs & Aging.